

New York State Proficiency Test January 2007
Summary of Results

| | TM161 | TM162 | TM163 | TM164 | TM165 | Average bias | | TM161 | TM162 | TM163 | TM164 | TM165 | Average bias |
|--|-------|-------|-------|-------|-------|--------------|--|-------|-------|-------|-------|-------|--------------|
| CA125 all lab mean: | | | | | | | CA125 TOSOH AIA (TOM/TO1) mean: | | | | | | |
| mean | 26.1 | 49.2 | 18.5 | 43.5 | 42.1 | | mean | 27.9 | 54.9 | 20.2 | 49.5 | 44.7 | |
| SD | 3.6 | 5.7 | 2.5 | 5.4 | 5.6 | | SD | 1.4 | 1.6 | 0.6 | 2.4 | 3.0 | |
| %CV | 13.8% | 11.7% | 13.7% | 12.4% | 13.3% | | %CV | 5.0% | 2.9% | 3.1% | 4.8% | 6.8% | |
| N | 121 | 119 | 121 | 119 | 121 | | N | 4 | 4 | 4 | 4 | 4 | |
| mean+3SD | 36.9 | 66.5 | 26.1 | 59.7 | 58.9 | | mean+3SD | 32.1 | 59.6 | 22.0 | 56.6 | 53.8 | |
| mean-3SD | 15.3 | 32.0 | 10.9 | 27.3 | 25.4 | | mean-3SD | 23.8 | 50.2 | 18.3 | 42.3 | 35.6 | |
| mean/all kit median | 1.01 | 0.99 | 0.98 | 1.00 | 1.01 | 1.00 | kit median | 27.9 | 55.5 | 20.3 | 48.7 | 44.0 | |
| | | | | | | | mean/all kit median | 1.08 | 1.10 | 1.07 | 1.14 | 1.07 | 1.09 |
| | | | | | | | | | | | | | |
| CA125 TOSOH ST A1A-pack (TOM/TO2) mean: | | | | | | | CA125 DPC Immulite 2500 (DPF/DP5) mean: | | | | | | |
| mean | 32.4 | 67.0 | 25.3 | 60.7 | 54.7 | | mean | 24.9 | 50.6 | 19.1 | 43.5 | 41.8 | |
| SD | 1.9 | 4.8 | 2.5 | 5.3 | 3.7 | | N | 2 | 2 | 2 | 2 | 2 | |
| %CV | 6.0% | 7.2% | 9.9% | 8.7% | 6.7% | | mean/all kit median | 0.97 | 1.02 | 1.01 | 1.00 | 1.00 | 1.00 |
| N | 3 | 3 | 3 | 3 | 3 | | | | | | | | |
| mean+3SD | 38.2 | 81.4 | 32.8 | 76.5 | 65.7 | | CA125 Bayer ADVIA-Centaur (COB/BA1) mean: | | | | | | |
| mean-3SD | 26.6 | 52.5 | 17.8 | 45.0 | 43.7 | | mean | 25.8 | 48.7 | 18.9 | 43.5 | 41.2 | |
| kit median | 33.2 | 68.4 | 25.2 | 60.5 | 56.7 | | SD | 2.3 | 4.2 | 1.7 | 1.9 | 2.9 | |
| mean/all kit median | 1.26 | 1.35 | 1.34 | 1.40 | 1.31 | 1.33 | %CV | 8.8% | 8.6% | 8.9% | 4.4% | 7.1% | |
| | | | | | | | N | 30 | 30 | 30 | 28 | 30 | |
| CA125 Abbott Asxym (ABB/AB1) mean: | | | | | | | mean+3SD | 32.6 | 61.3 | 24.0 | 49.3 | 50.0 | |
| mean | 30.1 | 54.2 | 20.8 | 51.0 | 48.7 | | mean-3SD | 19.0 | 36.1 | 13.9 | 37.8 | 32.4 | |
| SD | 2.9 | 4.1 | 2.4 | 3.9 | 4.5 | | kit median | 26.4 | 48.9 | 19.0 | 43.9 | 41.6 | |
| %CV | 9.8% | 7.6% | 11.5% | 7.6% | 9.3% | | mean/all kit median | 1.00 | 0.98 | 1.00 | 1.00 | 0.99 | 0.99 |
| N | 18 | 17 | 18 | 18 | 18 | | | | | | | | |
| mean+3SD | 38.9 | 66.6 | 28.0 | 62.6 | 62.2 | | CA125 DPC Immulite 1000 (DPB/DP5) mean: | | | | | | |
| mean-3SD | 21.3 | 41.9 | 13.6 | 39.4 | 35.1 | | mean | 25.1 | 48.0 | 18.3 | 42.4 | 41.8 | |
| kit median | 29.7 | 54.0 | 20.9 | 51.8 | 50.2 | | SD | 1.6 | 3.1 | 2.0 | 2.0 | 1.4 | |
| mean/all kit median | 1.17 | 1.09 | 1.10 | 1.17 | 1.17 | 1.14 | %CV | 6.2% | 6.5% | 11.0% | 4.7% | 3.4% | |
| | | | | | | | N | 5 | 5 | 5 | 5 | 5 | |
| CA125 Beckman Unicel & Access (BCU & BCX/BC1) mean: | | | | | | | mean+3SD | 29.7 | 57.4 | 24.4 | 48.4 | 46.1 | |
| mean | 28.9 | 55.9 | 20.6 | 47.6 | 45.0 | | mean-3SD | 20.4 | 38.6 | 12.2 | 36.4 | 37.5 | |
| SD | 3.1 | 4.8 | 1.7 | 4.5 | 5.5 | | kit median | 25.0 | 46.5 | 18.8 | 43.4 | 42.2 | |
| %CV | 10.7% | 8.5% | 8.3% | 9.4% | 12.1% | | mean/all kit median | 0.97 | 0.96 | 0.97 | 0.98 | 1.00 | 0.98 |
| N | 9 | 9 | 9 | 9 | 9 | | | | | | | | |
| mean+3SD | 38.1 | 70.2 | 25.7 | 60.9 | 61.4 | | CA125 DPC Immulite 2000 (DPD/DP5) mean: | | | | | | |
| mean-3SD | 19.6 | 41.6 | 15.5 | 34.2 | 28.6 | | mean | 25.7 | 49.8 | 17.7 | 41.8 | 41.7 | |
| kit median | 29.0 | 55.3 | 21.0 | 48.0 | 47.1 | | SD | 1.8 | 2.6 | 1.2 | 2.0 | 2.8 | |
| mean/all kit median | 1.12 | 1.12 | 1.09 | 1.10 | 1.08 | 1.10 | %CV | 7.0% | 5.2% | 6.9% | 4.8% | 6.6% | |
| | | | | | | | N | 27 | 27 | 27 | 27 | 27 | |
| | | | | | | | mean+3SD | 31.2 | 57.5 | 21.3 | 47.7 | 50.0 | |
| | | | | | | | mean-3SD | 20.3 | 42.1 | 14.0 | 35.8 | 33.4 | |
| | | | | | | | kit median | 25.3 | 49.5 | 17.7 | 41.5 | 42.0 | |
| | | | | | | | mean/all kit median | 1.00 | 1.00 | 0.93 | 0.96 | 1.00 | 0.98 |

New York State Proficiency Test January 2007
Summary of Results

| | TM161 | TM162 | TM163 | TM164 | TM165 | Average bias | | TM161 | TM162 | TM163 | TM164 | TM165 | Average bias |
|---|-------|-------|-------|-------|-------|--------------|---|-------|-------|-------|-------|-------|--------------|
| CA125 Elecsys & E170 (BME & BMR/BM1) mean: | | | | | | | CA125 Johnson & Johnson Vitros (JJC/JJ1) mean: | | | | | | |
| mean | 22.0 | 40.3 | 16.3 | 37.3 | 35.2 | | mean | 20.5 | 44.4 | 14.1 | 36.3 | 35.5 | |
| SD | 1.7 | 2.1 | 1.4 | 2.6 | 2.5 | | SD | 1.2 | 1.8 | 1.3 | 0.9 | 2.4 | |
| %CV | 7.7% | 5.3% | 8.4% | 7.0% | 7.1% | | %CV | 6.0% | 4.2% | 9.3% | 2.5% | 6.9% | |
| N | 15 | 15 | 15 | 15 | 15 | | N | 6 | 6 | 6 | 6 | 6 | |
| mean+3SD | 27.1 | 46.7 | 20.4 | 45.1 | 42.6 | | mean+3SD | 24.2 | 50.0 | 18.0 | 39.1 | 42.8 | |
| mean-3SD | 16.9 | 34.0 | 12.2 | 29.4 | 27.7 | | mean-3SD | 16.8 | 38.9 | 10.2 | 33.6 | 28.2 | |
| kit median | 22.1 | 40.5 | 16.6 | 37.7 | 35.8 | | kit median | 20.4 | 43.6 | 13.6 | 36.4 | 35.0 | |
| mean/all kit median | 0.85 | 0.81 | 0.86 | 0.86 | 0.84 | 0.85 | mean/all kit median | 0.80 | 0.89 | 0.74 | 0.84 | 0.85 | 0.82 |
| CA125 kit average: | | | | | | | CA125 Fujirebio/Centocor (GAA/CE1) mean: | | | | | | |
| mean | 25.5 | 50.5 | 18.6 | 44.0 | 41.4 | | mean | 17.1 | 41.9 | 13.9 | 30.1 | 25.2 | |
| SD | 4.4 | 7.5 | 3.2 | 8.2 | 7.7 | | N | 2 | 2 | 2 | 2 | 2 | |
| all kit median | 25.7 | 49.8 | 18.9 | 43.5 | 41.8 | | mean/all kit median | 0.66 | 0.84 | 0.73 | 0.69 | 0.60 | 0.71 |

| | TM161 | TM162 | TM163 | TM164 | TM165 | | TM161 | TM162 | TM163 | TM164 | TM165 | | |
|--|-------|-------|-------|-------|-------|------|--|-------|-------|-------|-------|-------|------|
| CA27.29 all lab mean: | | | | | | | CA27.29 Bayer ACS-180 (COS/BA1) mean: | | | | | | |
| mean | 30.8 | 42.1 | 24.1 | 64.0 | 36.7 | | mean | 30.5 | 45.0 | 20.0 | 71.0 | 37.2 | |
| SD | 2.9 | 3.2 | 3.3 | 5.5 | 3.5 | | SD | 3.7 | 1.7 | 3.7 | 6.6 | 5.7 | |
| %CV | 9.3% | 7.6% | 13.7% | 8.6% | 9.6% | | %CV | 12.0% | 3.8% | 18.2% | 9.4% | 15.3% | |
| N | 52 | 52 | 52 | 52 | 52 | | N | 3 | 3 | 3 | 3 | 3 | |
| mean+3SD | 39.4 | 51.7 | 34.0 | 80.5 | 47.3 | | mean+3SD | 41.5 | 50.1 | 31.0 | 90.9 | 54.3 | |
| mean-3SD | 22.2 | 32.4 | 14.2 | 47.6 | 26.1 | | mean-3SD | 19.5 | 39.9 | 9.1 | 51.0 | 20.1 | |
| mean/all kit median | 0.99 | 0.94 | 0.94 | 0.93 | 0.97 | 0.95 | kit median | 32.6 | 44.9 | 20.2 | 72.8 | 38.9 | |
| | | | | | | | mean/all kit median | 0.98 | 1.01 | 0.78 | 1.03 | 0.98 | 0.95 |
| CA27.29 TOSOH ST A1A-pack (TOM/TO2) mean: | | | | | | | CA27.29 Bayer ADVIA-Centaur (COB/BA1) mean: | | | | | | |
| mean | 35.7 | 45.5 | 28.1 | 71.6 | 41.5 | | mean | 30.4 | 41.5 | 23.9 | 62.8 | 36.2 | |
| SD | 0.1 | 0.8 | 2.2 | 4.2 | 0.7 | | SD | 2.7 | 3.2 | 3.0 | 4.8 | 3.4 | |
| %CV | 0.3% | 1.7% | 7.8% | 5.9% | 1.6% | | %CV | 8.9% | 7.7% | 12.6% | 7.7% | 9.3% | |
| N | 3 | 3 | 3 | 3 | 3 | | N | 43 | 43 | 43 | 43 | 43 | |
| mean+3SD | 36.1 | 47.8 | 34.7 | 84.3 | 43.6 | | mean+3SD | 38.5 | 51.0 | 32.9 | 77.3 | 46.3 | |
| mean-3SD | 35.4 | 43.1 | 21.6 | 59.0 | 39.5 | | mean-3SD | 22.3 | 31.9 | 14.8 | 48.2 | 26.2 | |
| kit median | 35.8 | 45.7 | 27.7 | 72.1 | 41.3 | | kit median | 30.5 | 41.3 | 23.4 | 62.4 | 36.0 | |
| mean/all kit median | 1.14 | 1.02 | 1.10 | 1.04 | 1.10 | 1.08 | mean/all kit median | 0.97 | 0.93 | 0.93 | 0.91 | 0.96 | 0.94 |
| CA27.29 TOSOH AIA (TOM/TO1) mean: | | | | | | | CA27.29 kit average: | | | | | | |
| mean | 31.9 | 44.4 | 27.4 | 67.4 | 38.6 | | mean | 32.1 | 44.1 | 24.9 | 68.2 | 38.4 | |
| SD | 1.2 | 1.6 | 1.7 | 0.6 | 1.9 | | SD | 2.5 | 1.8 | 3.7 | 4.1 | 2.3 | |
| %CV | 3.8% | 3.7% | 6.4% | 0.8% | 5.0% | | all kit median | 31.2 | 44.7 | 25.6 | 69.2 | 37.9 | |
| N | 3 | 3 | 3 | 3 | 3 | | | | | | | | |
| mean+3SD | 35.5 | 49.3 | 32.6 | 69.1 | 44.3 | | | | | | | | |
| mean-3SD | 28.3 | 39.5 | 22.2 | 65.7 | 32.9 | | | | | | | | |
| kit median | 31.3 | 45.3 | 28.0 | 67.2 | 37.7 | | | | | | | | |
| mean/all kit median | 1.02 | 0.99 | 1.07 | 0.97 | 1.02 | 1.02 | | | | | | | |

New York State Proficiency Test January 2007
Summary of Results

| | TM161 | TM162 | TM163 | TM164 | TM165 | Average bias | | TM161 | TM162 | TM163 | TM164 | TM165 | Average bias |
|--|-------|-------|-------|-------|-------|--------------|---|-------|-------|-------|-------|-------|--------------|
| CA15-3 all lab mean: | | | | | | | CA15-3 Elecsys & E170 (BME & BMR/BM1) mean: | | | | | | |
| mean | 39.3 | 53.1 | 31.6 | 82.5 | 46.5 | | mean | 29.6 | 39.0 | 23.9 | 59.4 | 34.3 | |
| SD | 11.0 | 15.6 | 8.7 | 24.2 | 13.6 | | SD | 1.4 | 2.1 | 1.3 | 2.2 | 1.0 | |
| %CV | 28.0% | 29.4% | 27.5% | 29.4% | 29.2% | | %CV | 4.6% | 5.3% | 5.3% | 3.7% | 3.0% | |
| N | 51 | 51 | 51 | 51 | 51 | | N | 6 | 6 | 6 | 6 | 6 | |
| mean+3SD | 72.4 | 100.0 | 57.8 | 155.2 | 87.3 | | mean+3SD | 33.7 | 45.2 | 27.8 | 66.0 | 37.4 | |
| mean-3SD | 6.3 | 6.2 | 5.5 | 9.8 | 5.7 | | mean-3SD | 25.5 | 32.7 | 20.1 | 52.8 | 31.3 | |
| mean/all kit median | 1.16 | 1.17 | 1.17 | 1.16 | 1.17 | 1.17 | kit median | 29.8 | 39.3 | 23.6 | 60.1 | 34.7 | |
| | | | | | | | mean/all kit median | 0.88 | 0.86 | 0.88 | 0.84 | 0.86 | 0.86 |
| CA15-3 DPC Immulite 1000/2000 (DPB & DPD/DP5) mean: | | | | | | | CA15-3 Beckman Unicel & Access (BCU & BCX/BC1) mean: | | | | | | |
| mean | 59.0 | 81.3 | 47.3 | 125.4 | 71.0 | | mean | 29.0 | 38.7 | 23.3 | 57.9 | 33.2 | |
| SD | 5.1 | 7.4 | 2.4 | 11.4 | 4.4 | | SD | 1.7 | 1.6 | 0.8 | 1.4 | 0.6 | |
| %CV | 8.6% | 9.1% | 5.1% | 9.1% | 6.1% | | %CV | 6.0% | 4.1% | 3.5% | 2.4% | 1.8% | |
| N | 9 | 9 | 9 | 9 | 9 | | N | 6 | 6 | 6 | 6 | 6 | |
| mean+3SD | 74.1 | 103.4 | 54.6 | 159.6 | 84.1 | | mean+3SD | 34.2 | 43.4 | 25.8 | 62.0 | 35.0 | |
| mean-3SD | 43.8 | 59.1 | 40.1 | 91.3 | 57.9 | | mean-3SD | 23.8 | 34.0 | 20.9 | 53.8 | 31.3 | |
| kit median | 58.0 | 83.0 | 47.2 | 124.0 | 71.7 | | kit median | 29.0 | 39.0 | 23.6 | 58.2 | 33.3 | |
| mean/all kit median | 1.74 | 1.80 | 1.74 | 1.76 | 1.78 | 1.77 | mean/all kit median | 0.86 | 0.86 | 0.86 | 0.81 | 0.83 | 0.84 |
| CA15-3 Abbott Asxym (ABB/AB1) mean: | | | | | | | CA15-3 Johnson & Johnson Vitros (JJC/JJ1) mean: | | | | | | |
| mean | 39.4 | 51.8 | 33.0 | 83.5 | 47.2 | | mean | 27.8 | 38.4 | 22.7 | 61.1 | 33.6 | |
| SD | 2.8 | 4.0 | 1.8 | 3.3 | 3.2 | | SD | 0.8 | 1.6 | 0.6 | 4.6 | 1.4 | |
| %CV | 7.1% | 7.8% | 5.5% | 3.9% | 6.8% | | %CV | 2.7% | 4.2% | 2.6% | 7.5% | 4.0% | |
| N | 5 | 5 | 5 | 5 | 5 | | N | 3 | 3 | 3 | 3 | 3 | |
| mean+3SD | 47.8 | 63.9 | 38.4 | 93.4 | 56.8 | | mean+3SD | 30.1 | 43.3 | 24.4 | 74.9 | 37.6 | |
| mean-3SD | 31.1 | 39.8 | 27.6 | 73.6 | 37.6 | | mean-3SD | 25.5 | 33.6 | 20.9 | 47.3 | 29.5 | |
| kit median | 38.8 | 49.6 | 32.4 | 83.6 | 48.0 | | kit median | 28.0 | 38.1 | 22.9 | 62.4 | 34.3 | |
| mean/all kit median | 1.17 | 1.15 | 1.22 | 1.17 | 1.19 | 1.18 | mean/all kit median | 0.82 | 0.85 | 0.84 | 0.86 | 0.84 | 0.84 |
| CA15-3 Bayer ADVIA-Centaur (COB/BA1) mean: | | | | | | | CA15-3 kit average: | | | | | | |
| mean | 38.0 | 51.5 | 30.3 | 81.2 | 45.3 | | mean | 37.1 | 50.1 | 30.1 | 78.1 | 44.1 | |
| SD | 2.8 | 4.2 | 2.4 | 5.3 | 3.5 | | SD | 11.8 | 16.5 | 9.4 | 25.8 | 14.6 | |
| %CV | 7.5% | 8.1% | 7.8% | 6.6% | 7.6% | | all kit median | 33.8 | 45.2 | 27.1 | 71.2 | 39.8 | |
| N | 19 | 19 | 19 | 19 | 19 | | | | | | | | |
| mean+3SD | 46.5 | 64.0 | 37.5 | 97.2 | 55.7 | | | | | | | | |
| mean-3SD | 29.5 | 38.9 | 23.2 | 65.2 | 35.0 | | | | | | | | |
| kit median | 38.5 | 51.5 | 31.0 | 81.1 | 44.8 | | | | | | | | |
| mean/all kit median | 1.12 | 1.14 | 1.12 | 1.14 | 1.14 | 1.13 | | | | | | | |

New York State Proficiency Test January 2007
Summary of Results

| | TM161 | TM162 | TM163 | TM164 | TM165 | Average bias | | TM161 | TM162 | TM163 | TM164 | TM165 | Average bias |
|---|-------|-------|-------|-------|-------|--------------|--|-------|-------|-------|-------|-------|--------------|
| CA19-9 all lab mean: | | | | | | | CA19-9 Roche Elecsys & E170 (BME & BMR/BM1) mean: | | | | | | |
| mean | 50.1 | 43.6 | 22.7 | 35.1 | 63.0 | | mean | 32.7 | 33.5 | 16.9 | 29.1 | 47.8 | |
| SD | 14.6 | 10.3 | 5.7 | 7.6 | 15.6 | | SD | 1.7 | 1.9 | 1.4 | 2.8 | 2.3 | |
| %CV | 29.2% | 23.7% | 25.2% | 21.7% | 24.8% | | %CV | 5.1% | 5.6% | 8.2% | 9.7% | 4.8% | |
| mean+3SD | 93.9 | 74.6 | 39.9 | 58.0 | 109.8 | | mean+3SD | 37.8 | 39.2 | 21.1 | 37.5 | 54.7 | |
| mean-3SD | 6.2 | 12.6 | 5.6 | 12.3 | 16.2 | | mean-3SD | 27.7 | 27.9 | 12.8 | 20.7 | 40.9 | |
| N | 54 | 54 | 54 | 54 | 54 | | N | 5 | 5 | 5 | 5 | 5 | |
| mean/all kit median | 1.39 | 1.27 | 1.27 | 1.18 | 1.33 | 1.29 | kit median | 33.6 | 34.8 | 17.1 | 28.2 | 47.2 | |
| | | | | | | | mean/all kit median | 0.91 | 0.97 | 0.94 | 0.98 | 1.01 | 0.96 |
| CA19-9 Fujirebio/Centocor (GAA/CE1) mean: | | | | | | | CA19-9 Beckman Unicel (BCU/BC1) mean: | | | | | | |
| mean | 53.0 | 52.7 | 30.5 | 44.0 | 75.0 | | mean | 38.8 | 31.0 | 16.3 | 25.1 | 46.7 | |
| N | 2 | 2 | 2 | 2 | 2 | | SD | 1.7 | 0.9 | 0.5 | 1.7 | 2.1 | |
| mean/all kit median | 1.47 | 1.53 | 1.70 | 1.48 | 1.59 | 1.55 | %CV | 4.4% | 3.0% | 2.8% | 6.8% | 4.5% | |
| | | | | | | | mean+3SD | 43.9 | 33.9 | 17.6 | 30.1 | 52.9 | |
| CA19-9 Bayer ADVIA-Centaur (COB/BA1) mean: | | | | | | | mean-3SD | 33.7 | 28.2 | 14.9 | 20.0 | 40.4 | |
| mean | 61.9 | 51.5 | 26.7 | 40.3 | 74.9 | | N | 6 | 6 | 6 | 6 | 6 | |
| SD | 4.4 | 3.2 | 2.6 | 3.6 | 5.8 | | kit median | 38.9 | 31.2 | 16.2 | 25.1 | 47.0 | |
| %CV | 7.0% | 6.2% | 9.6% | 8.9% | 7.7% | | mean/all kit median | 1.08 | 0.90 | 0.91 | 0.84 | 0.99 | 0.94 |
| mean+3SD | 74.9 | 61.0 | 34.4 | 51.1 | 92.3 | | CA19-9 Beckman Access (BCX/BC1) mean: | | | | | | |
| mean-3SD | 48.8 | 42.0 | 19.1 | 29.5 | 57.5 | | mean | 35.8 | 29.8 | 15.1 | 23.2 | 45.1 | |
| N | 30 | 30 | 30 | 30 | 30 | | SD | 1.2 | 0.5 | 0.7 | 0.8 | 0.3 | |
| kit median | 61.5 | 51.1 | 26.2 | 39.8 | 75.7 | | %CV | 3.3% | 1.6% | 4.4% | 3.4% | 0.6% | |
| mean/all kit median | 1.72 | 1.50 | 1.49 | 1.35 | 1.59 | 1.53 | mean+3SD | 39.4 | 31.2 | 17.1 | 25.6 | 45.8 | |
| | | | | | | | mean-3SD | 32.2 | 28.4 | 13.1 | 20.9 | 44.3 | |
| CA19-9 DPC Immulite 2000 (DPD/DP5) mean: | | | | | | | N | 4 | 4 | 4 | 4 | 4 | |
| mean | 36.2 | 38.0 | 18.9 | 30.5 | 53.3 | | kit median | 35.8 | 29.9 | 15.3 | 23.1 | 45.1 | |
| SD | 1.1 | 2.0 | 1.7 | 1.3 | 2.7 | | mean/all kit median | 0.99 | 0.87 | 0.84 | 0.78 | 0.95 | 0.89 |
| %CV | 3.1% | 5.4% | 9.1% | 4.3% | 5.0% | | CA19-9 TOSOH ST-A1A (TOM/TO2) mean: | | | | | | |
| mean+3SD | 39.5 | 44.1 | 24.1 | 34.4 | 61.3 | | mean | 19.9 | 23.0 | 12.7 | 24.2 | 28.8 | |
| mean-3SD | 32.9 | 31.9 | 13.8 | 26.6 | 45.4 | | N | 2 | 2 | 2 | 2 | 2 | |
| N | 3 | 3 | 3 | 3 | 3 | | mean/all kit median | 0.55 | 0.67 | 0.71 | 0.81 | 0.61 | 0.67 |
| kit median | 36.0 | 38.7 | 18.2 | 29.8 | 53.3 | | CA19-9 TOSOH A1A (TOM/TO1) mean: | | | | | | |
| mean/all kit median | 1.01 | 1.10 | 1.06 | 1.02 | 1.13 | 1.06 | mean | 27.0 | 35.3 | 19.4 | 35.6 | 45.0 | |
| | | | | | | | N | 2 | 2 | 2 | 2 | 2 | |
| CA19-9 kit average: | | | | | | | mean/all kit median | 0.75 | 1.03 | 1.08 | 1.19 | 0.95 | 1.00 |
| mean | | | | | | | mean | 38.1 | 36.9 | 19.6 | 31.5 | 52.1 | |
| SD | | | | | | | SD | 13.5 | 10.4 | 6.1 | 7.8 | 15.8 | |
| all kit median | | | | | | | all kit median | 36.0 | 34.4 | 17.9 | 29.8 | 47.2 | |

New York State Proficiency Test January 2007
Summary of Results

| | TM161 | TM162 | TM163 | TM164 | TM165 | Average bias | | TM161 | TM162 | TM163 | TM164 | TM165 | Average bias |
|--|-------|-------|-------|-------|-------|--------------|---|-------|-------|-------|-------|-------|--------------|
| CEA all lab mean: | | | | | | | CEA DPC Immulite 2000 (DPD/DP5) mean: | | | | | | |
| mean | 12.6 | 13.9 | 4.8 | 10.5 | 13.9 | | mean | 14.2 | 15.9 | 4.9 | 11.6 | 15.6 | |
| SD | 1.7 | 1.9 | 0.6 | 1.4 | 1.7 | | SD | 0.7 | 0.9 | 0.4 | 0.7 | 0.9 | |
| %CV | 13.6% | 13.8% | 13.2% | 13.4% | 12.5% | | %CV | 5.1% | 5.5% | 7.2% | 6.3% | 5.6% | |
| mean+3SD | 17.8 | 19.7 | 6.6 | 14.7 | 19.1 | | mean+3SD | 16.4 | 18.5 | 6.0 | 13.8 | 18.2 | |
| mean-3SD | 7.5 | 8.2 | 2.9 | 6.3 | 8.7 | | mean-3SD | 12.1 | 13.3 | 3.9 | 9.4 | 13.0 | |
| N | 181 | 180 | 177 | 178 | 177 | | N | 17 | 17 | 17 | 17 | 17 | |
| mean/all kit median | 0.99 | 0.98 | 0.98 | 0.97 | 0.95 | 0.97 | kit median | 14.0 | 16.1 | 5.0 | 11.6 | 15.8 | |
| | | | | | | | mean/all kit median | 1.11 | 1.12 | 1.01 | 1.08 | 1.07 | 1.08 |
| CEA TOSOH ST-AIA (TOM/TO2) mean: | | | | | | | CEA DPC Immulite 2500 (DPF/DP5) mean: | | | | | | |
| mean | 17.0 | 19.8 | 7.2 | 15.2 | 20.8 | | mean | 14.3 | 15.7 | 4.7 | 11.4 | 16.2 | |
| SD | 0.7 | 0.2 | 0.3 | 0.8 | 1.0 | | N | 2 | 2 | 2 | 2 | 2 | |
| %CV | 4.0% | 1.2% | 4.5% | 5.2% | 4.9% | | mean/all kit median | 1.12 | 1.11 | 0.96 | 1.05 | 1.11 | 1.07 |
| mean+3SD | 19.0 | 20.5 | 8.1 | 17.6 | 23.9 | | | | | | | | |
| mean-3SD | 14.9 | 19.1 | 6.2 | 12.8 | 17.8 | | | | | | | | |
| N | 3 | 3 | 3 | 3 | 3 | | | | | | | | |
| kit median | 17.2 | 19.7 | 7.3 | 15.5 | 20.3 | | | | | | | | |
| mean/all kit median | 1.33 | 1.40 | 1.47 | 1.41 | 1.43 | 1.41 | | | | | | | |
| CEA TOSOH AIA (TOM/TO1) mean: | | | | | | | CEA Bayer ADVIA-Centaur (COB/BA1) mean: | | | | | | |
| mean | 13.3 | 16.0 | 5.6 | 12.2 | 16.3 | | mean | 13.7 | 14.7 | 5.1 | 11.4 | 14.6 | |
| SD | 0.4 | 0.4 | 0.3 | 0.3 | 0.6 | | SD | 0.8 | 0.7 | 0.3 | 0.6 | 1.0 | |
| %CV | 3.1% | 2.4% | 4.5% | 2.8% | 3.6% | | %CV | 5.8% | 4.6% | 6.5% | 5.6% | 6.6% | |
| mean+3SD | 14.5 | 17.2 | 6.3 | 13.2 | 18.0 | | mean+3SD | 16.0 | 16.7 | 6.1 | 13.3 | 17.5 | |
| mean-3SD | 12.1 | 14.9 | 4.8 | 11.2 | 14.6 | | mean-3SD | 11.3 | 12.7 | 4.1 | 9.5 | 11.7 | |
| N | 4 | 4 | 4 | 4 | 4 | | N | 58 | 56 | 57 | 58 | 58 | |
| kit median | 13.5 | 16.2 | 5.6 | 12.3 | 16.4 | | kit median | 13.7 | 14.7 | 5.1 | 11.4 | 14.6 | |
| mean/all kit median | 1.04 | 1.13 | 1.14 | 1.13 | 1.12 | 1.11 | mean/all kit median | 1.07 | 1.03 | 1.05 | 1.05 | 1.00 | 1.04 |
| CEA Bayer ACS-180 (COS/BA1) mean: | | | | | | | CEA Johnson & Johnson Vitros (JJC/JJ1) mean: | | | | | | |
| mean | 13.9 | 15.7 | 5.5 | 12.3 | 15.4 | | mean | 12.8 | 14.7 | 5.4 | 11.2 | 15.3 | |
| SD | 0.7 | 0.2 | 0.0 | 0.8 | 0.8 | | SD | 0.7 | 0.8 | 0.8 | 0.7 | 0.8 | |
| %CV | 5.0% | 1.0% | 0.0% | 6.5% | 5.1% | | %CV | 5.4% | 5.6% | 15.1% | 6.7% | 5.1% | |
| mean+3SD | 16.0 | 16.2 | 5.5 | 14.7 | 17.7 | | mean+3SD | 14.9 | 17.2 | 7.8 | 13.4 | 17.7 | |
| mean-3SD | 11.8 | 15.3 | 5.5 | 9.9 | 13.1 | | mean-3SD | 10.7 | 12.2 | 2.9 | 9.0 | 13.0 | |
| N | 3 | 3 | 3 | 3 | 3 | | N | 10 | 10 | 10 | 10 | 9 | |
| kit median | 14.3 | 15.7 | 5.5 | 12.0 | 15.8 | | kit median | 12.8 | 14.8 | 5.4 | 11.5 | 15.5 | |
| mean/all kit median | 1.09 | 1.11 | 1.13 | 1.14 | 1.06 | 1.10 | mean/all kit median | 1.00 | 1.04 | 1.10 | 1.04 | 1.05 | 1.04 |

New York State Proficiency Test January 2007
Summary of Results

| | TM161 | TM162 | TM163 | TM164 | TM165 | Average bias | | TM161 | TM162 | TM163 | TM164 | TM165 | Average bias |
|--|-------|-------|-------|-------|-------|--------------|---|-------|-------|-------|-------|-------|--------------|
| CEA DPC Immulite 1000 (DPB/DP5) mean: | | | | | | | CEA Beckman Access (BCX/BC1) mean: | | | | | | |
| mean | 13.4 | 14.2 | 4.5 | 10.7 | 14.3 | | mean | 11.0 | 11.7 | 4.1 | 9.2 | 11.6 | |
| SD | 1.5 | 1.7 | 0.7 | 1.5 | 1.8 | | SD | 0.5 | 0.6 | 0.2 | 0.4 | 0.5 | |
| %CV | 11.3% | 11.7% | 15.7% | 14.1% | 12.3% | | %CV | 4.2% | 5.3% | 4.5% | 4.1% | 3.9% | |
| mean+3SD | 17.9 | 19.2 | 6.7 | 15.2 | 19.6 | | mean+3SD | 12.4 | 13.5 | 4.6 | 10.3 | 12.9 | |
| mean-3SD | 8.8 | 9.2 | 2.4 | 6.1 | 9.0 | | mean-3SD | 9.6 | 9.9 | 3.5 | 8.1 | 10.2 | |
| N | 4 | 4 | 4 | 4 | 4 | | N | 16 | 16 | 16 | 16 | 16 | |
| kit median | 14.1 | 14.8 | 4.8 | 11.1 | 15.0 | | kit median | 11.0 | 11.8 | 4.1 | 9.2 | 11.6 | |
| mean/all kit median | 1.04 | 1.00 | 0.93 | 0.99 | 0.98 | 0.99 | mean/all kit median | 0.86 | 0.82 | 0.84 | 0.85 | 0.79 | 0.83 |
| CEA Abbott Architect (ABH/AB1) mean: | | | | | | | CEA Roche E170 (BMR/BM1) mean: | | | | | | |
| mean | 11.9 | 13.8 | 5.1 | 10.8 | 14.3 | | mean | 10.2 | 11.6 | 4.0 | 8.5 | 12.0 | |
| N | 2 | 2 | 2 | 2 | 2 | | SD | 0.4 | 0.5 | 0.1 | 0.3 | 0.5 | |
| mean/all kit median | 0.93 | 0.97 | 1.05 | 1.00 | 0.98 | 0.98 | %CV | 3.5% | 4.4% | 3.5% | 3.6% | 3.9% | |
| CEA Abbott Imx (ABM/AB1) mean: | | | | | | | CEA Roche Elecsys (BME/BM1) mean: | | | | | | |
| mean | 12.5 | 14.1 | 4.6 | 9.9 | 14.8 | | mean | 9.7 | 10.9 | 3.8 | 8.0 | 11.2 | |
| N | 2 | 2 | 2 | 2 | 2 | | SD | 0.6 | 0.6 | 0.2 | 0.5 | 0.7 | |
| mean/all kit median | 0.98 | 0.99 | 0.93 | 0.92 | 1.01 | 0.97 | %CV | 5.8% | 5.5% | 5.7% | 6.6% | 6.4% | |
| CEA Abbott Asxym (ABB/AB1) mean: | | | | | | | CEA kit average: | | | | | | |
| mean | 12.2 | 14.1 | 4.9 | 10.1 | 14.2 | | mean | 12.8 | 14.3 | 4.9 | 10.8 | 14.6 | |
| SD | 1.3 | 1.1 | 0.5 | 0.9 | 1.2 | | SD | 1.8 | 2.3 | 0.8 | 1.8 | 2.4 | |
| %CV | 10.3% | 8.0% | 9.6% | 8.9% | 8.7% | | all kit median | 12.8 | 14.2 | 4.9 | 10.8 | 14.6 | |
| mean+3SD | 16.0 | 17.4 | 6.3 | 12.8 | 17.9 | | | | | | | | |
| mean-3SD | 8.5 | 10.7 | 3.5 | 7.4 | 10.5 | | | | | | | | |
| N | 23 | 23 | 23 | 23 | 23 | | | | | | | | |
| kit median | 12.2 | 14.1 | 4.8 | 10.1 | 14.1 | | | | | | | | |
| mean/all kit median | 0.96 | 0.99 | 1.00 | 0.93 | 0.97 | 0.97 | | | | | | | |
| CEA Beckman Unicel (BCU/BC1) mean: | | | | | | | | | | | | | |
| mean | 11.4 | 11.9 | 4.3 | 9.6 | 12.4 | | | | | | | | |
| SD | 0.4 | 0.5 | 0.4 | 0.7 | 0.7 | | | | | | | | |
| %CV | 3.9% | 4.5% | 8.6% | 7.0% | 5.4% | | | | | | | | |
| mean+3SD | 12.7 | 13.5 | 5.4 | 11.6 | 14.4 | | | | | | | | |
| mean-3SD | 10.1 | 10.3 | 3.2 | 7.6 | 10.4 | | | | | | | | |
| N | 13 | 13 | 13 | 12 | 13 | | | | | | | | |
| kit median | 11.3 | 12.2 | 4.4 | 9.7 | 12.3 | | | | | | | | |
| mean/all kit median | 0.89 | 0.84 | 0.88 | 0.89 | 0.85 | 0.87 | | | | | | | |

New York State Proficiency Test January 2007
Summary of Results

| | TM161 | TM162 | TM163 | TM164 | TM165 | Average bias | | TM161 | TM162 | TM163 | TM164 | TM165 | Average bias |
|--|-------|-------|-------|-------|-------|--------------|---|-------|-------|-------|-------|-------|--------------|
| AFP all lab mean: | | | | | | | AFP DPC Immulite 2000 (DPD/DP5) mean: | | | | | | |
| mean | 9.5 | 13.9 | 23.0 | 17.3 | 28.4 | | mean | 9.6 | 14.0 | 22.8 | 17.4 | 28.6 | |
| SD | 0.7 | 0.9 | 1.7 | 1.3 | 2.3 | | SD | 0.7 | 0.8 | 1.2 | 1.0 | 1.8 | |
| %CV | 7.5% | 6.6% | 7.4% | 7.6% | 8.1% | | %CV | 7.5% | 5.7% | 5.4% | 5.9% | 6.4% | |
| mean+3SD | 11.7 | 16.6 | 28.1 | 21.2 | 35.3 | | mean+3SD | 11.8 | 16.4 | 26.5 | 20.5 | 34.1 | |
| mean-3SD | 7.4 | 11.1 | 17.9 | 13.4 | 21.5 | | mean-3SD | 7.5 | 11.6 | 19.1 | 14.3 | 23.2 | |
| N | 99 | 98 | 99 | 98 | 102 | | N | 23 | 22 | 23 | 23 | 23 | |
| mean/target | 1.00 | 0.99 | 0.97 | 0.97 | 0.95 | 0.98 | kit median | 9.5 | 14.0 | 22.7 | 17.2 | 28.7 | |
| | | | | | | | mean/target | 1.01 | 1.00 | 0.96 | 0.97 | 0.96 | 0.98 |
| AFP TOSOH ST-A1A (TOM/TO2) mean: | | | | | | | AFP Beckman Unicel (BCU/BC1) mean: | | | | | | |
| mean | 9.9 | 14.8 | 24.4 | 19.3 | 30.8 | | mean | 9.2 | 13.8 | 23.2 | 17.8 | 28.8 | |
| SD | 0.4 | 0.9 | 0.7 | 0.6 | 1.0 | | SD | 0.7 | 0.8 | 2.6 | 2.5 | 2.7 | |
| %CV | 3.6% | 5.8% | 2.7% | 2.9% | 3.1% | | %CV | 7.9% | 5.6% | 11.3% | 14.0% | 9.2% | |
| mean+3SD | 10.9 | 17.4 | 26.4 | 21.0 | 33.7 | | mean+3SD | 11.4 | 16.1 | 31.0 | 25.3 | 36.8 | |
| mean-3SD | 8.8 | 12.2 | 22.4 | 17.6 | 27.9 | | mean-3SD | 7.1 | 11.5 | 15.3 | 10.3 | 20.9 | |
| N | 3 | 3 | 3 | 3 | 3 | | N | 11 | 11 | 11 | 11 | 11 | |
| kit median | 9.9 | 14.9 | 24.1 | 19.4 | 30.4 | | kit median | 9.3 | 13.9 | 23.3 | 17.8 | 28.9 | |
| mean/target | 1.04 | 1.06 | 1.03 | 1.08 | 1.03 | 1.05 | mean/target | 0.97 | 0.98 | 0.98 | 0.99 | 0.97 | 0.98 |
| AFP DPC Immulite 1000 (DPB/DP5) mean: | | | | | | | AFP Bayer ADVIDA Centaur (COB/BA1) mean: | | | | | | |
| mean | 9.9 | 14.8 | 24.1 | 18.3 | 30.2 | | mean | 9.7 | 13.9 | 22.9 | 17.0 | 27.4 | |
| SD | 0.4 | 0.3 | 1.5 | 0.8 | 1.1 | | SD | 0.8 | 0.9 | 0.9 | 0.9 | 1.2 | |
| %CV | 4.5% | 2.0% | 6.1% | 4.5% | 3.5% | | %CV | 8.5% | 6.6% | 4.0% | 5.2% | 4.4% | |
| mean+3SD | 11.2 | 15.7 | 28.5 | 20.8 | 33.4 | | mean+3SD | 12.2 | 16.7 | 25.6 | 19.7 | 31.0 | |
| mean-3SD | 8.5 | 13.9 | 19.7 | 15.8 | 27.1 | | mean-3SD | 7.2 | 11.2 | 20.1 | 14.3 | 23.8 | |
| N | 4 | 4 | 4 | 4 | 4 | | N | 24 | 24 | 24 | 24 | 24 | |
| kit median | 9.8 | 14.8 | 23.8 | 18.2 | 30.3 | | kit median | 9.8 | 14.0 | 23.2 | 17.0 | 27.7 | |
| mean/target | 1.04 | 1.06 | 1.02 | 1.02 | 1.01 | 1.03 | mean/target | 1.02 | 0.99 | 0.96 | 0.95 | 0.92 | 0.97 |
| AFP Roche E170 (BMR/BM1) mean: | | | | | | | AFP Abbott Asxym (ABB/AB1) mean: | | | | | | |
| mean | 9.3 | 14.1 | 23.8 | 18.1 | 29.9 | | mean | 9.6 | 13.5 | 22.8 | 17.3 | 28.9 | |
| SD | 0.5 | 0.8 | 1.2 | 1.2 | 1.5 | | SD | 0.6 | 1.0 | 2.2 | 1.4 | 2.0 | |
| %CV | 5.6% | 5.6% | 4.9% | 6.8% | 5.0% | | %CV | 5.9% | 7.1% | 9.5% | 8.1% | 7.0% | |
| mean+3SD | 10.9 | 16.5 | 27.2 | 21.8 | 34.4 | | mean+3SD | 11.3 | 16.4 | 29.3 | 21.5 | 35.0 | |
| mean-3SD | 7.8 | 11.8 | 20.3 | 14.3 | 25.4 | | mean-3SD | 7.9 | 10.6 | 16.4 | 13.1 | 22.9 | |
| N | 8 | 8 | 8 | 8 | 8 | | N | 14 | 14 | 14 | 14 | 14 | |
| kit median | 9.4 | 14.3 | 23.7 | 17.6 | 29.4 | | kit median | 9.7 | 13.4 | 22.2 | 17.9 | 29.1 | |
| mean/target | 0.98 | 1.01 | 1.00 | 1.01 | 1.00 | 1.00 | mean/target | 1.01 | 0.96 | 0.96 | 0.97 | 0.97 | 0.97 |

New York State Proficiency Test January 2007
Summary of Results

| | TM161 | TM162 | TM163 | TM164 | TM165 | Average bias | | TM161 | TM162 | TM163 | TM164 | TM165 | Average bias | |
|---|-------|-------|-------|-------|-------|--------------|---|-------------------|--------------|--------------|--------------|--------------|--------------|--|
| AFP Roche Elecsys (BME/BM1) mean: | | | | | | | AFP Bayer ACS 180 (COS/BA1) mean: | | | | | | | |
| mean | 9.1 | 13.2 | 21.6 | 16.6 | 27.6 | | mean | 8.2 | 11.6 | 21.6 | 14.6 | 24.5 | | |
| SD | 0.7 | 1.0 | 1.7 | 1.3 | 2.0 | | N | 2 | 2 | 2 | 2 | 2 | | |
| %CV | 7.9% | 7.3% | 7.7% | 8.1% | 7.2% | | mean/target | 0.86 | 0.83 | 0.91 | 0.82 | 0.82 | 0.85 | |
| mean+3SD | 11.2 | 16.1 | 26.5 | 20.7 | 33.5 | | AFP Johnson & Johnson Vitros (JJC/JJ1) mean: | | | | | | | |
| mean-3SD | 6.9 | 10.3 | 16.6 | 12.6 | 21.6 | | mean | 8.3 | 12.0 | 19.3 | 14.4 | 23.9 | | |
| N | 4 | 4 | 4 | 4 | 4 | | SD | 0.1 | 0.4 | 0.7 | 0.6 | 0.5 | | |
| kit median | 9.0 | 13.1 | 21.2 | 16.4 | 27.1 | 0.93 | %CV | 0.7% | 3.1% | 3.7% | 4.2% | 2.1% | | |
| mean/target | 0.95 | 0.94 | 0.91 | 0.93 | 0.92 | | mean+3SD | 8.4 | 13.2 | 21.5 | 16.2 | 25.4 | | |
| AFP Beckman Access (BCX/BC1) mean: | | | | | | | | mean-3SD | 8.1 | 10.9 | 17.1 | 12.6 | 22.4 | |
| mean | 8.6 | 12.9 | 21.6 | 16.4 | 27.2 | | N | 3 | 3 | 3 | 3 | 3 | | |
| SD | 1.5 | 2.5 | 4.1 | 3.1 | 4.4 | | kit median | 8.3 | 12.2 | 19.1 | 14.1 | 23.9 | | |
| %CV | 17.9% | 19.5% | 19.1% | 18.6% | 16.0% | | mean/target | 0.87 | 0.86 | 0.81 | 0.80 | 0.80 | 0.83 | |
| mean+3SD | 13.2 | 20.4 | 34.0 | 25.6 | 40.3 | | AFP | | | | | | | |
| mean-3SD | 4.0 | 5.4 | 9.2 | 7.2 | 14.1 | | | TM161 | TM162 | TM163 | TM164 | TM165 | | |
| N | 3 | 3 | 3 | 3 | 3 | 0.91 | *IS target | 9.5 | 14.0 | 23.7 | 17.9 | 29.8 | | |
| kit median | 9.3 | 14.3 | 23.9 | 17.8 | 29.5 | | SD (+/-) | 0.29 | 0.69 | 1.7 | 1.15 | 2.35 | | |
| mean/target | 0.90 | 0.92 | 0.91 | 0.92 | 0.91 | | % CV | 3.0% | 4.9% | 7.2% | 6.4% | 7.9% | | |
| AFP kit average: | | | | | | | | high (30%) | 12.4 | 18.2 | 30.8 | 23.3 | 38.7 | |
| mean | 9.2 | 13.5 | 22.5 | 17.0 | 28.0 | | low (30%) | 6.7 | 9.8 | 16.6 | 12.5 | 20.9 | | |
| SD | 0.6 | 1.0 | 1.5 | 1.5 | 2.2 | | * target value from a traceable AFP standard | | | | | | | |
| all kit median | 9.3 | 13.8 | 22.8 | 17.3 | 28.6 | | | | | | | | | |

| | TM161 | TM162 | TM163 | TM164 | TM165 | | TM161 | TM162 | TM163 | TM164 | TM165 | | |
|--------------------------|-------|-------|-------|-------|-------|------|---|-------|-------|-------|-------|------|------|
| PSA all lab mean: | | | | | | | PSA Johnson & Johnson Vitros (JJC/JJ1) mean: | | | | | | |
| mean | 9.2 | 2.3 | 3.7 | 9.5 | 3.8 | | mean | 9.6 | 2.8 | 4.1 | 10.3 | 4.3 | |
| SD | 0.8 | 0.2 | 0.3 | 0.8 | 0.3 | | SD | 0.4 | 0.1 | 0.1 | 0.5 | 0.1 | |
| %CV | 8.6% | 8.9% | 8.1% | 8.4% | 8.3% | | %CV | 4.3% | 3.0% | 3.6% | 4.5% | 2.5% | |
| mean+3SD | 11.6 | 3.0 | 4.6 | 11.9 | 4.7 | | mean+3SD | 10.9 | 3.0 | 4.5 | 11.7 | 4.6 | |
| mean-3SD | 6.8 | 1.7 | 2.8 | 7.1 | 2.8 | | mean-3SD | 8.4 | 2.5 | 3.7 | 8.9 | 4.0 | |
| N | 275 | 275 | 275 | 275 | 275 | | N | 13 | 13 | 13 | 13 | 13 | |
| mean/target | 1.08 | 1.11 | 1.13 | 1.09 | 1.11 | 1.11 | kit median | 9.6 | 2.8 | 4.1 | 10.2 | 4.3 | |
| | | | | | | | mean/target | 1.13 | 1.32 | 1.24 | 1.19 | 1.26 | 1.23 |

New York State Proficiency Test January 2007
Summary of Results

| | TM161 | TM162 | TM163 | TM164 | TM165 | Average bias | | TM161 | TM162 | TM163 | TM164 | TM165 | Average bias |
|---|-------|-------|-------|-------|-------|--------------|---|-------|-------|-------|-------|-------|--------------|
| PSA TOSOH ST-AIA (TOM/TO2) mean: | | | | | | | PSA Bayer ACS180 (COS/BA1) mean: | | | | | | |
| mean | 9.9 | 2.7 | 4.1 | 10.9 | 4.2 | | mean | 9.4 | 2.5 | 3.7 | 9.5 | 3.9 | |
| SD | 0.6 | 0.4 | 0.3 | 1.0 | 0.4 | | SD | 0.6 | 0.1 | 0.4 | 0.5 | 0.1 | |
| %CV | 5.6% | 13.2% | 7.9% | 8.7% | 9.5% | | %CV | 6.9% | 2.4% | 11.0% | 5.2% | 3.2% | |
| mean+3SD | 11.6 | 3.7 | 5.0 | 13.7 | 5.4 | | mean+3SD | 11.4 | 2.6 | 4.9 | 11.0 | 4.3 | |
| mean-3SD | 8.2 | 1.6 | 3.1 | 8.0 | 3.0 | | mean-3SD | 7.5 | 2.3 | 2.5 | 8.0 | 3.5 | |
| N | 3 | 3 | 3 | 3 | 3 | | N | 4 | 4 | 4 | 4 | 4 | |
| kit median | 9.8 | 2.7 | 4.2 | 10.9 | 4.3 | | kit median | 9.3 | 2.5 | 3.9 | 9.7 | 3.9 | |
| mean/target | 1.16 | 1.27 | 1.23 | 1.25 | 1.25 | 1.23 | mean/target | 1.11 | 1.17 | 1.12 | 1.09 | 1.14 | 1.13 |
| PSA TOSOH AIA (TOM/TO1) mean: | | | | | | | PSA Abbott Architect (ABH/AB1) mean: | | | | | | |
| mean | 9.9 | 2.6 | 4.0 | 10.4 | 4.1 | | mean | 9.7 | 2.3 | 3.8 | 9.8 | 3.7 | |
| SD | 0.5 | 0.1 | 0.2 | 0.5 | 0.2 | | SD | 0.2 | 0.1 | 0.2 | 0.3 | 0.2 | |
| %CV | 4.9% | 5.2% | 5.7% | 4.9% | 4.7% | | %CV | 2.5% | 5.0% | 4.6% | 3.5% | 4.9% | |
| mean+3SD | 11.3 | 3.0 | 4.7 | 12.0 | 4.7 | | mean+3SD | 10.4 | 2.6 | 4.3 | 10.8 | 4.2 | |
| mean-3SD | 8.4 | 2.2 | 3.3 | 8.9 | 3.5 | | mean-3SD | 8.9 | 2.0 | 3.2 | 8.8 | 3.2 | |
| N | 10 | 10 | 10 | 10 | 10 | | N | 4 | 4 | 4 | 4 | 4 | |
| kit median | 10.1 | 2.6 | 4.1 | 10.5 | 4.1 | | kit median | 9.7 | 2.3 | 3.8 | 9.9 | 3.7 | |
| mean/target | 1.16 | 1.22 | 1.22 | 1.20 | 1.20 | 1.20 | mean/target | 1.14 | 1.10 | 1.14 | 1.12 | 1.09 | 1.12 |
| PSA Beckman Access (BCX/BC2) mean: | | | | | | | PSA Abbott IMX (ABM/AB1) mean: | | | | | | |
| mean | 10.0 | 2.5 | 4.0 | 10.4 | 4.1 | | mean | 9.3 | 2.4 | 3.8 | 9.8 | 3.9 | |
| SD | 0.5 | 0.1 | 0.2 | 0.4 | 0.2 | | N | 2 | 2 | 2 | 2 | 2 | |
| %CV | 5.1% | 4.2% | 3.9% | 4.1% | 3.8% | | mean/target | 1.09 | 1.12 | 1.14 | 1.12 | 1.13 | 1.12 |
| mean+3SD | 11.5 | 2.8 | 4.5 | 11.7 | 4.5 | | PSA Abbott Asxym (ABB/AB1) mean: | | | | | | |
| mean-3SD | 8.5 | 2.2 | 3.6 | 9.1 | 3.6 | | mean | 9.3 | 2.3 | 3.6 | 9.5 | 3.8 | |
| N | 43 | 43 | 43 | 43 | 43 | | SD | 0.6 | 0.1 | 0.2 | 0.6 | 0.2 | |
| kit median | 10.0 | 2.5 | 4.1 | 10.4 | 4.1 | | %CV | 6.3% | 4.7% | 6.9% | 5.9% | 5.2% | |
| mean/target | 1.18 | 1.19 | 1.23 | 1.20 | 1.20 | 1.20 | mean+3SD | 11.0 | 2.6 | 4.4 | 11.2 | 4.4 | |
| PSA Beckman Unicel (BCU/BC2) mean: | | | | | | | PSA Dade Behring Dimension (DUD/DA1) mean: | | | | | | |
| mean | 9.6 | 2.4 | 3.9 | 10.0 | 3.9 | | mean | 9.4 | 2.3 | 3.6 | 9.6 | 3.7 | |
| SD | 0.6 | 0.1 | 0.2 | 0.4 | 0.2 | | SD | 0.7 | 0.2 | 0.2 | 0.6 | 0.3 | |
| %CV | 6.3% | 5.6% | 6.1% | 3.7% | 5.8% | | %CV | 8.0% | 7.8% | 6.6% | 6.6% | 7.6% | |
| mean+3SD | 11.5 | 2.8 | 4.6 | 11.1 | 4.6 | | mean+3SD | 11.6 | 2.9 | 4.3 | 11.5 | 4.6 | |
| mean-3SD | 7.8 | 2.0 | 3.1 | 8.9 | 3.2 | | mean-3SD | 7.1 | 1.8 | 2.9 | 7.7 | 2.9 | |
| N | 16 | 16 | 16 | 16 | 16 | | N | 26 | 26 | 26 | 26 | 26 | |
| kit median | 9.7 | 2.4 | 3.9 | 10.0 | 3.9 | | kit median | 9.4 | 2.3 | 3.6 | 9.5 | 3.7 | |
| mean/target | 1.13 | 1.15 | 1.17 | 1.15 | 1.15 | 1.15 | mean/target | 1.10 | 1.11 | 1.10 | 1.10 | 1.10 | 1.10 |

New York State Proficiency Test January 2007
Summary of Results

| | TM161 | TM162 | TM163 | TM164 | TM165 | Average bias | | TM161 | TM162 | TM163 | TM164 | TM165 | Average bias |
|--|-------|-------|-------|-------|-------|--------------|--|--------------|--------------|--------------|--------------|--------------|--------------|
| PSA DPC Immulite 1000 (DPB/DP5) mean: | | | | | | | PSA Bayer ADVIA-Centaur (COB/BA1) mean: | | | | | | |
| mean | 9.0 | 2.2 | 3.8 | 9.4 | 3.7 | | mean | 8.7 | 2.3 | 3.6 | 8.9 | 3.6 | |
| SD | 0.3 | 0.1 | 0.1 | 0.4 | 0.2 | | SD | 0.6 | 0.1 | 0.2 | 0.4 | 0.2 | |
| %CV | 3.8% | 4.9% | 3.7% | 4.1% | 4.3% | | %CV | 6.9% | 5.0% | 5.5% | 4.8% | 5.1% | |
| mean+3SD | 10.0 | 2.5 | 4.2 | 10.6 | 4.1 | | mean+3SD | 10.5 | 2.6 | 4.2 | 10.2 | 4.2 | |
| mean-3SD | 8.0 | 1.9 | 3.3 | 8.2 | 3.2 | | mean-3SD | 6.9 | 1.9 | 3.0 | 7.6 | 3.1 | |
| N | 13 | 13 | 13 | 13 | 13 | | N | 56 | 56 | 56 | 56 | 56 | |
| kit median | 8.9 | 2.2 | 3.8 | 9.5 | 3.6 | | kit median | 8.6 | 2.3 | 3.6 | 8.9 | 3.6 | |
| mean/target | 1.06 | 1.04 | 1.14 | 1.08 | 1.08 | 1.08 | mean/target | 1.02 | 1.08 | 1.08 | 1.02 | 1.07 | 1.06 |
| PSA DPC Immulite 2000 (DPD/DP5) mean: | | | | | | | PSA Roche Elecsys (BME/BM1) mean: | | | | | | |
| mean | 9.1 | 2.2 | 3.6 | 9.2 | 3.6 | | mean | 8.2 | 2.1 | 3.3 | 8.3 | 3.3 | |
| SD | 0.8 | 0.2 | 0.2 | 0.7 | 0.2 | | SD | 0.7 | 0.1 | 0.2 | 0.6 | 0.3 | |
| %CV | 8.7% | 7.8% | 6.9% | 7.2% | 6.1% | | %CV | 8.5% | 7.1% | 5.9% | 6.6% | 7.7% | |
| mean+3SD | 11.4 | 2.7 | 4.3 | 11.2 | 4.2 | | mean+3SD | 10.3 | 2.5 | 3.9 | 10.0 | 4.1 | |
| mean-3SD | 6.7 | 1.7 | 2.8 | 7.2 | 2.9 | | mean-3SD | 6.1 | 1.6 | 2.7 | 6.7 | 2.5 | |
| N | 18 | 18 | 18 | 18 | 18 | | N | 18 | 18 | 18 | 18 | 18 | |
| kit median | 9.1 | 2.1 | 3.5 | 9.1 | 3.5 | | kit median | 8.2 | 2.0 | 3.4 | 8.2 | 3.3 | |
| mean/target | 1.07 | 1.05 | 1.08 | 1.06 | 1.04 | 1.06 | mean/target | 0.96 | 0.98 | 1.01 | 0.95 | 0.97 | 0.97 |
| PSA DPC Immulite 1000 & 2000 3G (DPB & DPD/DP6) mean: | | | | | | | PSA DPC Immulite 2500 (DPF/DP5) mean: | | | | | | |
| mean | 8.8 | 2.2 | 3.5 | 9.3 | 3.7 | | mean | 7.9 | 1.9 | 3.2 | 8.6 | 3.4 | |
| SD | 0.5 | 0.1 | 0.3 | 0.5 | 0.1 | | SD | 2 | 2 | 2 | 2 | 2 | |
| %CV | 5.6% | 3.7% | 7.5% | 4.9% | 3.5% | | mean/target | 0.93 | 0.90 | 0.95 | 0.98 | 0.99 | 0.95 |
| mean+3SD | 10.3 | 2.4 | 4.3 | 10.7 | 4.0 | | | | | | | | |
| mean-3SD | 7.3 | 2.0 | 2.7 | 8.0 | 3.3 | | | | | | | | |
| N | 4 | 4 | 4 | 4 | 4 | | | | | | | | |
| kit median | 9.0 | 2.2 | 3.5 | 9.4 | 3.7 | | PSA kit average: | | | | | | |
| mean/target | 1.04 | 1.05 | 1.07 | 1.07 | 1.07 | 1.06 | mean | 9.2 | 2.3 | 3.7 | 9.6 | 3.8 | |
| | | | | | | | SD | 0.6 | 0.2 | 0.3 | 0.7 | 0.3 | |
| | | | | | | | all kit median | 9.3 | 2.3 | 3.7 | 9.5 | 3.7 | |
| PSA Roche E170 (BMR/BM1) mean: | | | | | | | PSA | | | | | | |
| mean | 8.7 | 2.2 | 3.6 | 9.0 | 3.7 | | | TM161 | TM162 | TM163 | TM164 | TM165 | |
| SD | 0.5 | 0.1 | 0.2 | 0.3 | 0.1 | | * Assigned IS target | 8.5 | 2.1 | 3.3 | 8.7 | 3.4 | |
| %CV | 5.2% | 3.7% | 4.1% | 3.2% | 3.9% | | SD (+/-) | 0.4 | 0.1 | 0.2 | 0.4 | 0.2 | |
| mean+3SD | 10.1 | 2.5 | 4.1 | 9.9 | 4.1 | | % CV | 4.8% | 6.4% | 5.4% | 4.7% | 5.5% | |
| mean-3SD | 7.4 | 2.0 | 3.2 | 8.2 | 3.2 | | high (25%) | 10.6 | | | 10.9 | | |
| N | 15 | 15 | 15 | 15 | 15 | | low (25%) | 6.4 | | | 6.5 | | |
| kit median | 8.7 | 2.2 | 3.6 | 8.9 | 3.6 | | high (30%) | | 2.7 | 4.3 | | 4.4 | |
| mean/target | 1.03 | 1.07 | 1.11 | 1.04 | 1.07 | 1.06 | low (30%) | | 1.5 | 2.3 | | 2.4 | |
| | | | | | | | * target value from a traceable PSA standard | | | | | | |

New York State Proficiency Test January 2007
Summary of Results

| | TM161 | TM162 | TM163 | TM164 | TM165 | Average bias | | TM161 | TM162 | TM163 | TM164 | TM165 | Average bias |
|--|-------|-------|-------|-------|-------|--------------|--|--------------|--------------|--------------|--------------|--------------|--------------|
| free PSA all lab mean: | | | | | | | free PSA Dade Behring Dimension (DUD/DA1) mean: | | | | | | |
| mean | 2.20 | 0.29 | 0.96 | 1.19 | 0.47 | | mean | 1.89 | 0.25 | 0.76 | 0.96 | 0.39 | |
| SD | 0.44 | 0.06 | 0.19 | 0.22 | 0.08 | | SD | 0.31 | 0.01 | 0.07 | 0.05 | 0.03 | |
| %CV | 20.0% | 19.5% | 20.0% | 18.2% | 17.9% | | %CV | 16.3% | 5.7% | 9.6% | 4.7% | 8.7% | |
| mean+3SD | 3.52 | 0.45 | 1.53 | 1.84 | 0.72 | | mean+3SD | 2.82 | 0.29 | 0.98 | 1.09 | 0.50 | |
| mean-3SD | 0.88 | 0.12 | 0.38 | 0.54 | 0.22 | | mean-3SD | 0.97 | 0.21 | 0.54 | 0.82 | 0.29 | |
| N | 66 | 58 | 63 | 65 | 63 | | N | 5 | 4 | 5 | 5 | 5 | |
| mean/target | 1.06 | 1.15 | 1.31 | 1.18 | 1.17 | 1.18 | kit median | 2.06 | 0.26 | 0.75 | 0.97 | 0.40 | |
| | | | | | | | mean/target | 0.91 | 1.00 | 1.04 | 0.95 | 0.99 | 0.98 |
| free PSA Beckman Access (BCX/BC2) mean: | | | | | | | free PSA Roche E170 (BMR/BM1) mean: | | | | | | |
| mean | 2.42 | 0.33 | 1.08 | 1.40 | 0.55 | | mean | 1.85 | 0.23 | 0.79 | 1.00 | 0.39 | |
| SD | 0.42 | 0.03 | 0.09 | 0.09 | 0.04 | | SD | 0.25 | 0.03 | 0.07 | 0.06 | 0.03 | |
| %CV | 17.4% | 9.4% | 7.9% | 6.3% | 7.1% | | %CV | 13.6% | 10.9% | 8.5% | 6.1% | 6.7% | |
| mean+3SD | 3.69 | 0.43 | 1.34 | 1.67 | 0.67 | | mean+3SD | 2.60 | 0.31 | 0.99 | 1.18 | 0.47 | |
| mean-3SD | 1.16 | 0.24 | 0.83 | 1.14 | 0.43 | | mean-3SD | 1.09 | 0.15 | 0.59 | 0.82 | 0.31 | |
| N | 20 | 17 | 21 | 19 | 20 | | N | 10 | 8 | 8 | 10 | 9 | |
| kit median | 2.28 | 0.32 | 1.10 | 1.40 | 0.56 | | kit median | 1.80 | 0.23 | 0.76 | 1.00 | 0.39 | |
| mean/target | 1.17 | 1.33 | 1.49 | 1.39 | 1.37 | 1.35 | mean/target | 0.89 | 0.92 | 1.08 | 0.99 | 0.97 | 0.97 |
| free PSA Beckman Unicel (BCU/BC2) mean: | | | | | | | free PSA Abbott Asxym (ABB/AB1) mean: | | | | | | |
| mean | 2.56 | 0.33 | 1.10 | 1.37 | 0.52 | | mean | 1.89 | 0.22 | 0.72 | 1.02 | 0.36 | |
| SD | 0.38 | 0.04 | 0.11 | 0.11 | 0.05 | | SD | 0.22 | 0.01 | 0.07 | 0.10 | 0.02 | |
| %CV | 14.8% | 11.0% | 10.1% | 8.2% | 9.5% | | %CV | 11.6% | 4.5% | 10.2% | 10.0% | 5.8% | |
| mean+3SD | 3.70 | 0.44 | 1.44 | 1.70 | 0.67 | | mean+3SD | 2.55 | 0.25 | 0.94 | 1.33 | 0.42 | |
| mean-3SD | 1.43 | 0.22 | 0.77 | 1.03 | 0.37 | | mean-3SD | 1.24 | 0.19 | 0.50 | 0.72 | 0.29 | |
| N | 14 | 14 | 14 | 14 | 14 | | N | 4 | 3 | 3 | 4 | 3 | |
| kit median | 2.69 | 0.31 | 1.11 | 1.40 | 0.51 | | kit median | 1.93 | 0.22 | 0.75 | 1.01 | 0.35 | |
| mean/target | 1.24 | 1.31 | 1.51 | 1.35 | 1.30 | 1.34 | mean/target | 0.91 | 0.88 | 0.99 | 1.01 | 0.89 | 0.94 |
| free PSA Roche Elecsys (BME/BM1) mean: | | | | | | | free PSA DPC Immulite 2000 (DPD/DP5) mean: | | | | | | |
| mean | 1.95 | 0.26 | 0.90 | 1.03 | 0.42 | | mean | 1.87 | 0.20 | 0.65 | 0.90 | 0.35 | |
| SD | 0.21 | 0.03 | 0.21 | 0.11 | 0.04 | | SD | 0.06 | 0.02 | 0.05 | 0.02 | 0.02 | |
| %CV | 10.9% | 10.4% | 23.1% | 10.3% | 8.6% | | %CV | 2.9% | 10.6% | 6.9% | 2.6% | 4.9% | |
| mean+3SD | 2.59 | 0.34 | 1.52 | 1.35 | 0.53 | | mean+3SD | 2.04 | 0.26 | 0.79 | 0.97 | 0.40 | |
| mean-3SD | 1.31 | 0.18 | 0.28 | 0.71 | 0.31 | | mean-3SD | 1.71 | 0.13 | 0.52 | 0.83 | 0.30 | |
| N | 9 | 8 | 8 | 9 | 8 | | N | 3 | 3 | 3 | 3 | 3 | |
| kit median | 1.97 | 0.25 | 0.84 | 1.03 | 0.42 | | kit median | 1.87 | 0.19 | 0.65 | 0.91 | 0.36 | |
| mean/target | 0.94 | 1.04 | 1.23 | 1.02 | 1.05 | 1.06 | mean/target | 0.90 | 0.79 | 0.89 | 0.89 | 0.88 | 0.87 |
| free PSA kit average: | | | | | | | free PSA | TM161 | TM162 | TM163 | TM164 | TM165 | |
| mean | 2.1 | 0.3 | 0.9 | 1.1 | 0.4 | | * IS target | 2.07 | 0.25 | 0.73 | 1.01 | 0.40 | |
| SD | 0.3 | 0.1 | 0.2 | 0.2 | 0.1 | | SD (+/-) | 0.08 | 0.01 | 0.03 | 0.05 | 0.02 | |
| all kit median | 1.9 | 0.3 | 0.8 | 1.0 | 0.4 | | % CV | 4.0% | 5.1% | 4.5% | 4.7% | 4.8% | |
| | | | | | | | high (30%) | 2.69 | 0.33 | 0.95 | 1.31 | 0.52 | |
| | | | | | | | low (30%) | 1.45 | 0.18 | 0.51 | 0.71 | 0.28 | |

* target value from a traceable free PSA standard.

New York State Proficiency Test January 2007
Summary of Results

| | TM161 | TM162 | TM163 | TM164 | TM165 | Average bias | | TM161 | TM162 | TM163 | TM164 | TM165 | Average bias |
|---------------------------------|-------|-------|-------|-------|-------|--------------|---------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|
| % free PSA all lab mean: | | | | | | | % free PSA DA1/DA1 mean: | | | | | | |
| mean | 23.1 | 12.0 | 24.7 | 12.1 | 12.2 | | mean | 20.0 | 10.8 | 20.7 | 10.3 | 10.9 | |
| SD | 3.4 | 1.7 | 3.8 | 1.6 | 1.5 | | SD | 2.3 | 0.7 | 0.5 | 0.4 | 1.2 | |
| %CV | 14.7% | 14.0% | 15.4% | 13.2% | 12.5% | | %CV | 11.7% | 6.3% | 2.4% | 4.1% | 10.8% | |
| mean+3SD | 33.3 | 17.0 | 36.1 | 16.9 | 16.7 | | mean+3SD | 27.0 | 12.8 | 22.2 | 11.6 | 14.4 | |
| mean-3SD | 12.9 | 6.9 | 13.3 | 7.3 | 7.6 | | mean-3SD | 13.0 | 8.7 | 19.2 | 9.0 | 7.3 | |
| N | 55 | 43 | 51 | 50 | 54 | | N | 4 | 3 | 4 | 4 | 4 | |
| mean/target | 0.95 | 1.01 | 1.12 | 1.04 | 1.03 | 1.03 | kit median | 19.7 | 11.0 | 20.6 | 10.4 | 11.2 | |
| | | | | | | | mean/target | 0.82 | 0.90 | 0.94 | 0.89 | 0.92 | 0.89 |
| % free PSA BC2/BC2 mean: | | | | | | | | TM161 | TM162 | TM163 | TM164 | TM165 | |
| mean | 25.3 | 13.3 | 27.4 | 13.5 | 13.2 | | % free PSA DP5/DP5 mean: | | | | | | |
| SD | 3.6 | 1.0 | 2.4 | 1.1 | 1.0 | | mean | 22.1 | 10.0 | 19.2 | 10.3 | 9.9 | |
| %CV | 14.4% | 7.6% | 8.6% | 7.9% | 7.3% | | N | 2 | 1 | 2 | 2 | 2 | |
| mean+3SD | 36.2 | 16.3 | 34.5 | 16.7 | 16.1 | | mean/target | 0.91 | 0.84 | 0.87 | 0.88 | 0.84 | 0.87 |
| mean-3SD | 14.3 | 10.3 | 20.3 | 10.3 | 10.3 | | | | | | | | |
| N | 23 | 20 | 27 | 19 | 28 | | % free PSA kit average: | | | | | | |
| kit median | 24.1 | 13.0 | 27.8 | 13.9 | 13.1 | | mean | 22.3 | 11.3 | 22.4 | 11.4 | 11.3 | |
| mean/target | 1.04 | 1.12 | 1.24 | 1.16 | 1.12 | 1.14 | SD | 2.2 | 1.4 | 3.6 | 1.5 | 1.4 | |
| | | | | | | | all kit median | 21.9 | 10.9 | 21.6 | 10.8 | 11.0 | |
| % free PSA BM1/BM1 mean: | | | | | | | | | | | | | |
| mean | 21.7 | 11.0 | 22.5 | 11.3 | 11.1 | | % free PSA | TM161 | TM162 | TM163 | TM164 | TM165 | |
| SD | 2.4 | 1.2 | 1.5 | 0.8 | 0.9 | | IS target | 24.4% | 11.9% | 22.1% | 11.6% | 11.8% | |
| %CV | 11.0% | 10.9% | 6.9% | 7.1% | 8.2% | | | | | | | | |
| mean+3SD | 28.9 | 14.6 | 27.1 | 13.8 | 13.8 | | | | | | | | |
| mean-3SD | 14.6 | 7.4 | 17.8 | 8.9 | 8.4 | | | | | | | | |
| N | 18 | 13 | 12 | 17 | 14 | | | | | | | | |
| kit median | 21.4 | 11.0 | 23.0 | 11.1 | 11.0 | | | | | | | | |
| mean/target | 0.89 | 0.93 | 1.02 | 0.98 | 0.94 | 0.95 | | | | | | | |

| | TM161 | TM162 | TM163 | TM164 | TM165 | | TM161 | TM162 | TM163 | TM164 | TM165 |
|------------------------------------|-------|-------|-------|-------|-------|--------------------------------------|-------|-------|-------|-------|-------|
| complexed PSA all lab mean: | | | | | | % complexed PSA all lab mean: | | | | | |
| mean | 7.0 | 2.1 | 2.8 | 8.2 | 3.3 | mean | 79.4 | 91.8 | 80.6 | 89.3 | 91.8 |
| SD | 0.5 | 0.2 | 0.1 | 0.4 | 0.3 | SD | 9.3 | 11.3 | 9.8 | 7.6 | 11.1 |
| %CV | 7.8% | 8.4% | 5.1% | 5.5% | 8.7% | %CV | 11.8% | 12.4% | 12.2% | 8.5% | 12.1% |
| mean+3SD | 8.6 | 2.6 | 3.3 | 9.5 | 4.1 | mean+3SD | 107.4 | 125.9 | 110.1 | 112.0 | 125.2 |
| mean-3SD | 5.3 | 1.5 | 2.4 | 6.8 | 2.4 | mean-3SD | 51.3 | 57.8 | 51.0 | 66.5 | 58.4 |
| N | 12 | 12 | 12 | 12 | 12 | N | 11 | 11 | 11 | 11 | 11 |